The first three markers were chosen because they are involved in CRC tumorigenesis[30], whereas TYMS was analysed because it could be used to identify a subgroup of stage II colon cancer patients who better benefit from the use of adjuvant chemotherapy, as we pointed out in a previous study[31]. Here, TYMS is linked to malignant colon neoplasm.